Clinical TrialsThe Phase 3 COAST trial of sozinibercept in combination with Eylea in wet age-related macular degeneration failed to meet its primary endpoint, causing disappointment.
Financial ObligationsOpthea could be required to pay four times the amounts received upon termination of the DFA agreement, significantly impacting the company's solvency.
Investor ConfidenceFollowing the negative trial outcomes, the stock has been downgraded and the price target has been drastically reduced from $12 to $1.